Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour
European Journal of Cancer2014Vol. 50(17), pp. 3021–3028
Citations Over TimeTop 10% of 2014 papers
Silvia Stacchiotti, Monica Tortoreto, Giacomo Giulio Baldi, Giovanni Grignani, Angela Toss, Giuseppe Badalamenti, Denis Cominetti, Carlo Morosi, Angelo Paolo Dei Tos, Fabrizio Festinese, Elena Fumagalli, Salvatore Provenzano, Alessandro Gronchi, Elisabetta Pennacchioli, Tiziana Negri, Gian Paolo Dagrada, Rosalin Dolores Spagnuolo, S. Pilotti, Paolo G. Casali, Nadia Zaffaroni
Related Papers
- → Benefits of pazopanib over sunitinib for renal cell carcinoma(2016)6 cited
- → Cost Comparison in the Management of the Renal Cell Carcinoma with in Spain: Pazopanib vs. Sunitinib(2016)
- → Second line axitinib in metastatic renal cell carcinoma: Evaluation of prognostic factors influencing outcome.(2017)
- → Comparison of First-line Pazopanib and Sunitinib in Metastatic Renal Cell Carcinoma: Experiences of the Urologic Cancer Centre for Research and Innovation(2019)
- → Sunitinib Versus Pazopanib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate and Poor-Risk Characteristics: Real-World, a Single-Center(2023)